Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00532883 · ClinicalTrials.gov registry record · Phase 2
Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease
A Phase 2 study, sponsored by St. Jude Children's Research Hospital.
- Terminated
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT00532883: Clinical Trial Phase 2 study, sponsored by St. Jude Children's Research Hospital.
NCT00532883 is a Phase 2 study that was terminated before completion, run by St. Jude Children's Research Hospital. The registered enrollment target is 44 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00532883, a Phase 2 study, was terminated before completion, sponsored by St. Jude Children's Research Hospital.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited blood disease that can cause intense pain episodes. Hemoglobin SCD (HbSC) is a form of SCD that is characterized by dense red blood cells. The purpose of this study is to evaluate the safety and effectiveness of hydroxyurea and magnesium pidolate, alone and combined, at reducing red blood cell density and the frequency of pain episodes in people with HbSC.
Primary Outcome
An individuals' percentage of red blood cells with density greater than 41 g/dL as measured by Advia.
Interventions
- DRUG Hydroxyurea
- DRUG Magnesium Pidolate
- OTHER Placebo Pills and Placebo Liquid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2007-01 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Why NCT00532883 stopped before completion
NCT00532883 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 3 interventions - of which Hydroxyurea is the first listed.
NCT00532883 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00532883 about?
NCT00532883 is a clinical study titled "Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease". Sickle cell disease (SCD), also known as sickle cell anemia, is an inherited blood disease that can cause intense pain episodes. Hemoglobin SCD (HbSC) is a form of SCD that is characterized by dense red blood cells. The purpose of this study is to evaluate the safety and effectiveness of hydroxyurea...
What is the current status of trial NCT00532883?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2007-01. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00532883?
The interventions under investigation include: Hydroxyurea (DRUG), Magnesium Pidolate (DRUG), Placebo Pills and Placebo Liquid (OTHER).
Who is sponsoring clinical trial NCT00532883?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00532883's enrollment target sits among peer trials
44 1322nd of 2000 higher than 669 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia